Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Dependable recurring dividends from quality, high-yield stocks like these five are a recipe for passive income success.

Rising Demand for Targeted Therapies and Advancements in Genomic Technologies Propel the Personalized Medicine Biomarkers market to a 14.54% CAGR Akash Anand SNS Insider Pvt. Ltd 415-230-0044 email us ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...